Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, announced its participation in the H.C. Wainwright 26th Annual Global Healthcare Conference from September 9-11, 2024 in New York. The company will be involved in two key events:
1. A panel discussion on 'Cutting-Edge Approaches to Viral Hepatitis: Is a Cure on the Horizon?' on September 9, 2024, from 11:00-12:00PM ET, featuring Dr. Cassie Gorsuch, VP of Gene Therapy Discovery.
2. A fireside chat on September 10, 2024, from 5:00-5:30PM ET, which will be available via webcast on Precision's website for approximately 30 days after the event.
Precision BioSciences utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision.
Precision BioSciences (Nasdaq: DTIL), un'azienda all'avanguardia nel campo dell'editing genetico, ha annunciato la sua partecipazione alla 26ª Conferenza annuale globale sulla salute di H.C. Wainwright che si terrà dal 9 all'11 settembre 2024 a New York. L'azienda prenderà parte a due eventi principali:
1. Una discussione.panel su 'Approcci innovativi all'epatite virale: c'è una cura all'orizzonte?' che si terrà il 9 settembre 2024, dalle 11:00 alle 12:00 ET, con il Dr. Cassie Gorsuch, VP della scoperta di terapie geniche.
2. Un fireside chat il 10 settembre 2024, dalle 17:00 alle 17:30 ET, che sarà disponibile in diretta streaming sul sito web di Precision per circa 30 giorni dopo l'evento.
Precision BioSciences utilizza la sua piattaforma proprietaria ARCUS® per sviluppare terapie di editing genetico in vivo per modifiche genetiche sofisticate, incluso l'eliminazione, l'inserimento e l'escissione di geni.
Precision BioSciences (Nasdaq: DTIL), una empresa avanzada en edición genética, anunció su participación en la 26ª Conferencia Anual Global de Salud de H.C. Wainwright que se llevará a cabo del 9 al 11 de septiembre de 2024 en Nueva York. La empresa estará involucrada en dos eventos clave:
1. Un panel de discusión sobre 'Enfoques Innovadores para la Hepatitis Viral: ¿Hay una Cura a la Vista?' el 9 de septiembre de 2024, de 11:00 a 12:00 PM ET, con la Dra. Cassie Gorsuch, VP de Descubrimiento de Terapias Genéticas.
2. Un fireside chat el 10 de septiembre de 2024, de 5:00 a 5:30 PM ET, que estará disponible a través de una transmisión en vivo en el sitio web de Precision durante aproximadamente 30 días después del evento.
Precision BioSciences utiliza su plataforma propietaria ARCUS® para desarrollar terapias de edición genética in vivo para ediciones genéticas sofisticadas, incluyendo eliminación, inserción y escisión de genes.
Precision BioSciences (Nasdaq: DTIL)은 첨단 유전자 편집 회사로서, 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 글로벌 헬스케어 컨퍼런스에 참석한다고 발표했습니다. 이 회사는 두 가지 주요 이벤트에 참여할 예정입니다:
1. '바이러스성 간염에 대한 최첨단 접근: 치료 방법이 가까이 있을까?'라는 주제의 패널 토론이 2024년 9월 9일, ET 기준 오전 11시부터 오후 12시까지 진행되며, Cassie Gorsuch 박사(유전자 치료 발견 부사장)가 참여합니다.
2. 2024년 9월 10일, ET 기준 오후 5시부터 5시 30분까지 열리는 파이어사이드 차트가 진행되며, 이 이벤트는 Precision 웹사이트를 통해 약 30일간 웹캐스트로 제공됩니다.
Precision BioSciences는 자사의 독점 플랫폼 ARCUS®를 활용하여 유전자 제거, 삽입 및 절제를 포함한 정교한 유전자 편집을 위한 체내 유전자 편집 치료법을 개발하고 있습니다.
Precision BioSciences (Nasdaq: DTIL), une entreprise de pointe dans le domaine de l'édition génétique, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale de la Santé de H.C. Wainwright qui se déroulera du 9 au 11 septembre 2024 à New York. L'entreprise participera à deux événements clés :
1. Une discussion en panel sur 'Approches Innovantes pour l'Hépatite Virale : Une Guérison Est-elle à l'Horizon ?' le 9 septembre 2024, de 11h00 à 12h00 ET, avec le Dr Cassie Gorsuch, VP de la Découverte de Thérapies Thérapeutiques.
2. Un fireside chat le 10 septembre 2024, de 17h00 à 17h30 ET, qui sera disponible en direct sur le site de Precision pendant environ 30 jours après l'événement.
Precision BioSciences utilise sa plateforme propriétaire ARCUS® pour développer des thérapies d'édition génique in vivo pour des modifications génétiques sophistiquées, y compris l'élimination, l'insertion et l'excision de gènes.
Precision BioSciences (Nasdaq: DTIL), ein fortschrittliches Unternehmen für Gen-Editing, gab seine Teilnahme an der 26. jährlichen globalen Gesundheitskonferenz von H.C. Wainwright vom 9. bis 11. September 2024 in New York bekannt. Das Unternehmen wird an zwei wichtigen Veranstaltungen teilnehmen:
1. Eine Podiumsdiskussion mit dem Thema 'Innovative Ansätze zur Virushepatitis: Ist eine Heilung in Sicht?' am 9. September 2024 von 11:00 bis 12:00 Uhr ET, mit Dr. Cassie Gorsuch, VP für Entdeckung von Gentherapien.
2. Ein Fireside Chat am 10. September 2024 von 17:00 bis 17:30 Uhr ET, der etwa 30 Tage nach der Veranstaltung per Webcast auf der Website von Precision verfügbar sein wird.
Precision BioSciences nutzt seine proprietäre ARCUS®-Plattform, um in vivo Gentherapien für komplexe genetische Bearbeitungen, einschließlich Geneliminierung, -einfügung und -exzision, zu entwickeln.
- None.
- None.
Details are as follows:
Panel: Cutting-Edge Approaches to Viral Hepatitis: Is a Cure on the Horizon?
Date: September 9, 2024
Time: 11:00-12:00PM ET
Presenter: Cassie Gorsuch, Ph.D., Vice President, Gene Therapy Discovery
Fireside Chat:
Date: September 10, 2024
Time: 5:00-5:30PM ET
Webcast Registration: Link
The Fireside Chat will be available on Precision’s website in the Investors section under Events & Presentations on at investor.precisionbiosciences.com. An archived replay will be available for approximately 30 days following the event. Please contact your H.C. Wainwright representative for details regarding access to the panel presentation.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904336857/en/
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
Source: Precision BioSciences, Inc.
FAQ
When is Precision BioSciences (DTIL) participating in the H.C. Wainwright Global Healthcare Conference?
What events will Precision BioSciences (DTIL) be involved in at the conference?
Who will represent Precision BioSciences (DTIL) in the panel discussion?
How can investors access Precision BioSciences' (DTIL) fireside chat?
What is the main focus of Precision BioSciences' (DTIL) gene editing technology?
